E M Quinn1, C Fleming2, M J O'Sullivan2. 1. Department of Breast Surgery, Cork University Hospital, Cork, Ireland. edelquinn@rcsi.ie. 2. Department of Breast Surgery, Cork University Hospital, Cork, Ireland.
Abstract
BACKGROUND/AIMS: Adjuvant endocrine therapy for at least 5 years improves oncological outcomes in oestrogen receptor-positive breast cancer. Adherence rates to prescribed endocrine therapy are low and the search for modifiable causes of this continues. The aim of this study was to assess adherence rates in an Irish cohort of breast cancer patients prescribed adjuvant endocrine therapy and to assess modifiable factors associated with suboptimal adherence. METHODS: A cross-sectional anonymous survey was performed on 261 patients currently prescribed endocrine therapy. Data were collected regarding demographics, treatment, social and emotional factors and medication side effects. Each patient completed a medication adherence score and provided information about discontinuation of therapy and reasons for same. RESULTS: Only 67.8 % of patients assessed demonstrated complete medication adherence on the medication adherence scale. Twenty-nine patients (10.9 %) permanently stopped taking their prescribed endocrine therapy. Suboptimal adherence was more likely in younger patients (p < 0.001), those in employment (p = 0.005), those who experienced side effects (p = 0.006), those who perceived themselves to have low levels of emotional support (p < 0.001) and those who use the internet to read about their illness (p = 0.003). CONCLUSIONS: Endocrine therapy adherence is suboptimal in almost one-third of patients in our cohort. Appropriate assessment and management of side effects and negative emotions, combined with direction of patients to accurate internet sources of information, could help improve endocrine therapy adherence in women with early-stage breast cancer.
BACKGROUND/AIMS: Adjuvant endocrine therapy for at least 5 years improves oncological outcomes in oestrogen receptor-positive breast cancer. Adherence rates to prescribed endocrine therapy are low and the search for modifiable causes of this continues. The aim of this study was to assess adherence rates in an Irish cohort of breast cancerpatients prescribed adjuvant endocrine therapy and to assess modifiable factors associated with suboptimal adherence. METHODS: A cross-sectional anonymous survey was performed on 261 patients currently prescribed endocrine therapy. Data were collected regarding demographics, treatment, social and emotional factors and medication side effects. Each patient completed a medication adherence score and provided information about discontinuation of therapy and reasons for same. RESULTS: Only 67.8 % of patients assessed demonstrated complete medication adherence on the medication adherence scale. Twenty-nine patients (10.9 %) permanently stopped taking their prescribed endocrine therapy. Suboptimal adherence was more likely in younger patients (p < 0.001), those in employment (p = 0.005), those who experienced side effects (p = 0.006), those who perceived themselves to have low levels of emotional support (p < 0.001) and those who use the internet to read about their illness (p = 0.003). CONCLUSIONS: Endocrine therapy adherence is suboptimal in almost one-third of patients in our cohort. Appropriate assessment and management of side effects and negative emotions, combined with direction of patients to accurate internet sources of information, could help improve endocrine therapy adherence in women with early-stage breast cancer.
Entities:
Keywords:
Endocrine therapy; Hormone-positive breast cancer; Medication adherence
Authors: Andrea Markkula; Maria Hietala; Maria Henningson; Christian Ingvar; Carsten Rose; Helena Jernström Journal: Cancer Prev Res (Phila) Date: 2012-03-08
Authors: Uwe Güth; Mary Elizabeth Myrick; Nerbil Kilic; Serenella Eppenberger-Castori; Seraina Margaretha Schmid Journal: Breast Cancer Res Treat Date: 2012-01 Impact factor: 4.872
Authors: C Cluze; D Rey; L Huiart; M K BenDiane; A D Bouhnik; C Berenger; M P Carrieri; R Giorgi Journal: Ann Oncol Date: 2011-07-25 Impact factor: 32.976
Authors: H Wouters; G A Maatman; L Van Dijk; M L Bouvy; R Vree; E C G Van Geffen; J W Nortier; A M Stiggelbout Journal: Ann Oncol Date: 2013-05-23 Impact factor: 32.976
Authors: Kimberly R Jacob Arriola; Tamara A Mason; Kari Ann Bannon; Carol Holmes; Cecil Lamonte Powell; Kandra Horne; Ruth O'Regan Journal: Patient Educ Couns Date: 2014-01-10
Authors: Zerko Wako; Daniel Mengistu; Negalign Getahun Dinegde; Tseganesh Asefa; Mulugeta Wassie Journal: Breast Cancer (Dove Med Press) Date: 2021-06-09
Authors: P Chalela; E Munoz; D Inupakutika; S Kaghyan; D Akopian; V Kaklamani; K Lathrop; A Ramirez Journal: Contemp Clin Trials Commun Date: 2018-10-17